The total C-peptide Study Group list is appearing at the end of the article. mammalian sequence pattern of C-peptides includes four non-consecutive positions with glutamic acid, an interspaced glycine-rich segment, and some further residues. As a result, the C-peptide residue pattern provides a basis for ligand-receptor binding interactions. Their nature is yet unknown, but spacing is obviously important, in a manner like that seen for the major histocompatibility molecules, in which the residue spacing provides sites of defined interactions. [5, 6] These studies demonstrate a 25% increase when C-peptide was acutely raised to physiological lex;els, whereas further increases had no additional effect. [91 These findings correlate with measurements of increased glucose uptake by resting and exercising forearm muscle during C-peptide infusion. [1] and increased glucose uptake by muscle-strips from diabetic subjects. [11] However, in patients receiving C-peptide plus insulin for 3 months, blood glucose levels, indices of metabolic control, and insulin doses, were all unchanged as compared to non C-peptide treated controls. [7] The effects of C-peptide concerning two of the characteristic abnormalities in type 1 diabetes, i.e., impaired Na+, K+-ATPase activity and reduced endothelial function are probably more important than the C-peptide influence on [12] The COOH-terminal pentapeptide is as effective as the intact C-peptide molecule in stimulating Na+, K+-ATPase activity. [13] In addition, in endothelial cells the rise in Ca 2+ -concentration is accompanied by augmented activity of endothelial nitric oxide synthase (eNOS). [14] Furthermore, several findings suggest that C-peptide may interact with other hormones and growth factors. The effect of C-peptide on Na+,K+-ATPase is potentiated by the presence of sub-threshold concentrations of neuropeptide y. [12] Physiological Effects C-peptide has been found to elicit concentrationdependent stimulation of Na+, K + -ATPase activity in a variety of tissues including renal tubular cells, [12] rat sciatic nerve, [5, 16] pancreatic islets, [17. ] granulation tissue [161 and red blood cells. [14, 18] C-peptide exerts an ameliorating effect on the impaired deformability of red blood cells from type I diabetic patients, which is probably mediated via its effects on Na+, K + -ATPase. Further support for the C-peptide effects on Na+, K + -ATPase is provided by its effect on rat sciatic nerve Na+, K+-ATPase in type 1 diabetic BB/Wor-rats treated with C-peptide for 8 months. [15, 191 This effect is further substantiated by partial correction of the Na+, K + -ATPase associated defect in nerve conduction velocity and paranodal swelling, secondary to axonal Na + accumulation. [19] Furthermore, "m the C-peptide deficient diabetic BB/Wor-rat model the expression of both the insulin receptor and the IGF-I receptor mRNA and protein in peripheral nerve and brain tissue were normalized by C-peptide replacement, [2, 21] and the diabetes-induced hippocampal apoptosis was prevented by C-peptide replacement. [21] In type 1 diabetic patients, autonomic nerve function as measured by heart rate variability during deep breathing improves after intravenous C-peptide infusion for 3h, [22] and in months.
patients who receive C-peptide for 3 [7] A subgroup of the latter patients with signs of sensory neuropathy exhibits improved temperature threshold discrimination after C-peptide montts.
None of these replacement for 3 [7] effects are seen in patients who receive insulin therapy alone. [23] This is in keeping with the finding that C-peptide induces an increase in forearm blood flow in type 1 diabetic patients, which is blocked by a NO-synthase blocker. [24] It is also consistent with the demonstration of a C-peptide concentration-dependent dilatation of rat skeletal muscle arterioles in the presence of insulin.J251 C-peptide replacement in streptozotocin diabetic rats extending from 120 min to 14 days results in diminished glomerular hyperfiltration, increased functional reserve and reduced urinary albumin extraction. [26, 27] In addition, the renal weight tends to be lower and the glomerular volume was significantly smaller in C-peptide treated animals then in non-treated controls. [27] These data have been confirmed in clinical studies in patients with type 1 diabetes. Thus, C-peptide replacement during 3h and during 1 month in young patients with early signs of diabetic nephropathy, i.e., glomerular hyperfiltration but absence of manifest microalbuminuria, was accompanied by reduced glomerular hyperfiltration and decreased filtration fraction. [9'28] Furthermore, in a double-blind, randomized, cross-over stud) C-peptide replacement for 3 months in patients with microalbuminuria resulted in a 40% reduction in urinary albumin excretion. [7] It may be hypothesized that C-pepfide has the potential, via 
